317 related articles for article (PubMed ID: 31495087)
21. The molecular pathogenesis of craniopharyngiomas.
Campanini ML; Almeida JP; Martins CS; de Castro M
Arch Endocrinol Metab; 2023 Mar; 67(2):266-275. PubMed ID: 36748936
[TBL] [Abstract][Full Text] [Related]
22. Clinical and biological significance of adamantinomatous craniopharyngioma with CTNNB1 mutation.
Hara T; Akutsu H; Takano S; Kino H; Ishikawa E; Tanaka S; Miyamoto H; Sakamoto N; Hattori K; Sakata-Yanagimoto M; Chiba S; Hiyama T; Masumoto T; Matsumura A
J Neurosurg; 2018 Aug; 131(1):217-226. PubMed ID: 30074466
[TBL] [Abstract][Full Text] [Related]
23. Diagnosis and management of craniopharyngiomas in the era of genomics and targeted therapy.
Martinez-Gutierrez JC; D'Andrea MR; Cahill DP; Santagata S; Barker FG; Brastianos PK
Neurosurg Focus; 2016 Dec; 41(6):E2. PubMed ID: 27903124
[TBL] [Abstract][Full Text] [Related]
24. Craniopharyngiomas, including Recurrent Cases, Lack TERT Promoter Hotspot Mutations.
Fujio S; Juratli TA; Takajo T; Arita K; Nagano Y; Yoshimoto K; Nayyar N; Curry WT; Martinez-Lage M; Cahill DP; Barker FG; Brastianos PK
Neurol Med Chir (Tokyo); 2021 Jun; 61(6):385-391. PubMed ID: 33967180
[TBL] [Abstract][Full Text] [Related]
25. Comparative immunohistochemical expression of β-catenin, EGFR, ErbB2, and p63 in adamantinomatous and papillary craniopharyngiomas.
Esheba GE; Hassan AA
J Egypt Natl Canc Inst; 2015 Sep; 27(3):139-45. PubMed ID: 26198262
[TBL] [Abstract][Full Text] [Related]
26. Adamantinomatous and papillary craniopharyngiomas are characterized by distinct epigenomic as well as mutational and transcriptomic profiles.
Hölsken A; Sill M; Merkle J; Schweizer L; Buchfelder M; Flitsch J; Fahlbusch R; Metzler M; Kool M; Pfister SM; von Deimling A; Capper D; Jones DT; Buslei R
Acta Neuropathol Commun; 2016 Feb; 4():20. PubMed ID: 26927026
[TBL] [Abstract][Full Text] [Related]
27. BRAF V600E mutant papillary craniopharyngiomas: a single-institutional case series.
La Corte E; Younus I; Pivari F; Selimi A; Ottenhausen M; Forbes JA; Pisapia DJ; Dobri GA; Anand VK; Schwartz TH
Pituitary; 2018 Dec; 21(6):571-583. PubMed ID: 30187175
[TBL] [Abstract][Full Text] [Related]
28. BRAF V600E analysis for the differentiation of papillary craniopharyngiomas and Rathke's cleft cysts.
Schweizer L; Capper D; Hölsken A; Fahlbusch R; Flitsch J; Buchfelder M; Herold-Mende C; von Deimling A; Buslei R
Neuropathol Appl Neurobiol; 2015 Oct; 41(6):733-42. PubMed ID: 25442675
[TBL] [Abstract][Full Text] [Related]
29. Telomere length and Wnt/β-catenin pathway in adamantinomatous craniopharyngiomas.
Mota JIS; Silva-Júnior RMP; Martins CS; Bueno AC; Wildemberg LE; Antunes XLDS; Ozaki JGO; Coeli-Lacchini FB; Garcia-Peral C; Oliveira AER; Santos AC; Moreira AC; Machado HR; Dos Santos MV; Colli LM; Gadelha MR; Antonini SRR; de Castro M
Eur J Endocrinol; 2022 Jun; 187(2):219-230. PubMed ID: 35584004
[TBL] [Abstract][Full Text] [Related]
30. β-Catenin Attenuation Inhibits Tumor Growth and Promotes Differentiation in a BRAF
Zou M; BinEssa HA; Al-Malki YH; Al-Yahya S; Al-Alwan M; Al-Jammaz I; Khabar KSA; Almohanna F; Assiri AM; Meyer BF; Alzahrani AS; Al-Mohanna FA; Shi Y
Mol Cancer Ther; 2021 Sep; 20(9):1603-1613. PubMed ID: 34224366
[No Abstract] [Full Text] [Related]
31. Impact of the Canonical Wnt Pathway Activation on the Pathogenesis and Prognosis of Adamantinomatous Craniopharyngiomas.
Jucá CEB; Colli LM; Martins CS; Campanini ML; Paixão B; Jucá RV; Saggioro FP; de Oliveira RS; Moreira AC; Machado HR; Neder L; Antonini SR; de Castro M
Horm Metab Res; 2018 Jul; 50(7):575-581. PubMed ID: 29625497
[No Abstract] [Full Text] [Related]
32. CTNNB1 gene mutations, pituitary transcription factors, and MicroRNA expression involvement in the pathogenesis of adamantinomatous craniopharyngiomas.
Campanini ML; Colli LM; Paixao BM; Cabral TP; Amaral FC; Machado HR; Neder LS; Saggioro F; Moreira AC; Antonini SR; de Castro M
Horm Cancer; 2010 Aug; 1(4):187-96. PubMed ID: 21761366
[TBL] [Abstract][Full Text] [Related]
33. Biological Behaviour of Craniopharyngiomas.
Martinez-Barbera JP; Andoniadou CL
Neuroendocrinology; 2020; 110(9-10):797-804. PubMed ID: 32126562
[TBL] [Abstract][Full Text] [Related]
34. Potential evolution of neurosurgical treatment paradigms for craniopharyngioma based on genomic and transcriptomic characteristics.
Robinson LC; Santagata S; Hankinson TC
Neurosurg Focus; 2016 Dec; 41(6):E3. PubMed ID: 27903126
[TBL] [Abstract][Full Text] [Related]
35. Prediction of CTNNB1 Mutation Status in Pediatric Cystic Adamantinomatous Craniopharyngioma by Using Preoperative Magnetic Resonance Imaging Manifestation.
Zhu W; Tang T; Yuan S; Chang B; Li S; Chen M
Clin Neurol Neurosurg; 2021 Jan; 200():106347. PubMed ID: 33160718
[TBL] [Abstract][Full Text] [Related]
36. Papillary craniopharyngioma in a 4-year-old girl with BRAF V600E mutation: a case report and review of the literature.
Borrill R; Cheesman E; Stivaros S; Kamaly-Asl ID; Gnanalingham K; Kilday JP
Childs Nerv Syst; 2019 Jan; 35(1):169-173. PubMed ID: 30069716
[TBL] [Abstract][Full Text] [Related]
37. Sonic Hedgehog pathway is upregulated in adamantinomatous craniopharyngiomas.
Gomes DC; Jamra SA; Leal LF; Colli LM; Campanini ML; Oliveira RS; Martinelli CE; Elias PC; Moreira AC; Machado HR; Saggioro F; Neder L; Castro M; Antonini SR
Eur J Endocrinol; 2015 May; 172(5):603-8. PubMed ID: 25693592
[TBL] [Abstract][Full Text] [Related]
38. Gliosarcomas lack BRAF
Schwetye KE; Joseph NM; Al-Kateb H; Rich KM; Schmidt RE; Perry A; Gutmann DH; Dahiya S
Neuropathology; 2016 Oct; 36(5):448-455. PubMed ID: 26932501
[TBL] [Abstract][Full Text] [Related]
39. PROP1 and CTNNB1 expression in adamantinomatous craniopharyngiomas with or without β-catenin mutations.
Cani CM; Matushita H; Carvalho LR; Soares IC; Brito LP; Almeida MQ; Mendonça BB
Clinics (Sao Paulo); 2011; 66(11):1849-54. PubMed ID: 22086512
[TBL] [Abstract][Full Text] [Related]
40. Prediction of BRAF mutation status of craniopharyngioma using magnetic resonance imaging features.
Yue Q; Yu Y; Shi Z; Wang Y; Zhu W; Du Z; Yao Z; Chen L; Mao Y
J Neurosurg; 2018 Jul; 129(1):27-34. PubMed ID: 28984520
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
